CD8A and neoplasm: We have reported previously that DSP-0509 activated CD8 cells working in conjunction with anti-PD-1 antibodies and other immune checkpoint blockers (ICBs) in the tumor microenvironment and resulted in additive/synergistic anti-tumor activity [20].